阿斯利康AstraZeneca plc (AZN) 2016年年度报告「LSE」.pdf

1、What science can doAstraZeneca Annual Report and Form 20-F Information 2016We are a global,science-led biopharmaceutical business and in this Annual Report we report on the progress we made in 2016 in pushing the boundaries of science to deliver life-changing medicines.AstraZeneca.What science can d

2、o.Important information for readers of this Annual Report For more information in relation to the inclusion of reported?exchange rate(CER)growth rates as used in this Annual Report,please see the Financial Review on page 64.?239 are intended to provide a useful guide to terms and?acronyms and abbrev

3、iations,used in this Annual Report.Use of terms In this Annual Report,unless the context otherwise requires,AstraZeneca,the Group,we,us and our refer to AstraZeneca PLC and its consolidated entities.Cautionary statement regarding forward-looking statements A cautionary statement regarding forward-lo

4、oking statements and other essential information relating to this Annual Report can be found on page 243.Directors Report The following sections make up the Directors Report,?requirements of the Companies Act 2006:?Therapy Area Review Business Review Resources Review:including Employees Financial Re

5、view:Financial risk management Corporate Governance:including the Audit Committee Report and Corporate Governance Report Directors Responsibility Statement Development Pipeline Sustainability:supplementary information Shareholder Information Corporate InformationStrategic Report The following sectio

6、ns make up the Strategic Report,which has been prepared in accordance with the requirements of the Companies Act 2006:AstraZeneca at a glance?Strategy:including Risk overview Therapy Area Review Business Review Resources Review Financial ReviewWelcome to the AstraZeneca Annual Report and Form 20-F I